Skip to main content

Table 2 Factors associated with virological success at 30 months (n = 847)

From: Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults

 

Univariate analysis

Multivariate analysis

OR

95% CI

p

aOR

95% CI

p

HIV-1 DNA: < 3 vs. ≥ 3 log10 copies/million PBMC

1.44

0.99–2.07

0.05

1.57

1.08–2.30

0.02

CD4 count: < 500 vs ≥ 500 cells/mm3

1.11

0.77–1.61

0.58

1.15

0.78–1.68

0.48

Plasma RNA: < 5 vs ≥ 5 log10 copies/ml

1.20

0.82–1.75

0.35

   

Sex: male vs. female

1.32

0.82–2.15

0.25

1.15

0.69–1.91

0.60

Age: < 35 years vs. ≥ 35 years

0.60

0.42–0.87

0.01

0.62

0.42–0.91

0.01

WHO clinical stage: 1–2 vs. 3–4

0.76

0.39–1.47

0.41

   

IPT: received vs. not received

1.00

0.69–1.44

0.98

   

ART regimen

      

 TDF/FTC + LPV/r vs  TDF/FTC + EFV

0.56

0.37–0.85

0.01

0.59

0.39–0.91

0.02

 TDF/FTC + AZT vs  TDF/FTC + EFV

1.28

0.59–2.77

0.53

1.41

0.64–3.11

0.40

  1. n number of patients; OR odds ratio; aOR adjusted odds ratio; IPT 6-month isoniazide preventive therapy; CI confidence interval; DNA desoxyribonucleique acid; PBMC peripheral blood mononuclear cells; RNA ribonucleique acid; LPV/r lopinavir/ritonavir; AZT azidothymidine; EFV efavirenz; TDF tenofovir; FTC emtricitabine